James George Chopas
CIK 1836430 · VP/Chief Accounting Officer · last filed 2026-05-14
James George Chopas is a VP/Chief Accounting Officer who has filed 49 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for APLS, was dated May 14, 2026. Across all open-market trades the lifetime net is −$382.7K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
49
-$382.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | VP/Chief Accounting Officer | 8,075 | $41.03 | $331.3K | -$374.9K | 30 | 2026-05-14 |
| Radius Health, Inc. (RDUS) Delisted | Principal Finance Accounting | 6,701 | $30.00 | $201.0K | -$7.7K | 3 | 2021-03-09 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −104,361 | $0 | EDGAR |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +16,150 | $0 | EDGAR |
| 2026-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,064 | -$44.9K | EDGAR |
| 2026-01-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −2,064 | -$44.9K | EDGAR |
| 2026-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −726 | -$14.4K | EDGAR |
| 2026-01-20 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −726 | -$14.4K | EDGAR |
| 2026-01-15 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −873 | -$19.4K | EDGAR |
| 2026-01-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −873 | -$19.4K | EDGAR |
| 2025-09-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −189 | -$4.6K | EDGAR |
| 2025-09-15 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −189 | -$4.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.